Dementia and Alzheimer Disease

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Through a quantitative electroencephalogram, investigators observed brainwave changes in several regions of the brain following treatment with CT1812.

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 30, 2023.

The professor of neurology at the University of California, Irvine, talked about social determinants of health in Alzheimer disease and the importance of having diverse populations in clinical trials. [WATCH TIME: 4 minutes]

The associate professor at Johns Hopkins School of Nursing provided insight on a presentation at SLEEP 2023, and whether neurofilament light should be more considered when assessing elderly patients with sleep disorders. [WATCH TIME: 5 minutes]

With the approval, Roche has 3 FDA-cleared tests that are reflective of the main Alzheimer disease pathologies and help clinicians more completely define the disease biologically.

The associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromuscular disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 23, 2023.

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

Neurology News Network for the week ending June 17, 2023. [WATCH TIME: 3 minutes]

Over a 39-day period, treatment with SCI-110 resulted an average reduction of 23% in agitation among patients with Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and related disorders.

The FDA is set to make a final decision in July 2023, and if approved, lecanemab would join aducanumab as the only antiamyloid therapies available to treat early-stage Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 9, 2023.

According to a recent study presented at SLEEP 2023, the decline in MOCA scores in patients with mild cognitive impairment was associated with the degree of hypoxia observed from sleep studies.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Sleep Medicine.

Neurofilament light, a biomarker elevated in neurodegeneration and dementia, was higher among poor sleepers with Pittsburgh Sleep Quality Index scores of less than 5.

Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 2, 2023.

In July, the FDA is expected to make a decision on lecanemab (Leqembi), an antiamyloid therapy previously approved under the accelerated approval pathway, for a potential traditional approval for early-stage Alzheimer disease.

The professor of molecular neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed the premise behind a study of RNA-sequencing data to better understand the reasons why females suffer accelerated dementia. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.